Epistem plc, the UK biotechnology and personalised medicine company, has announced a partnership with The University of Manchester.
The two organisations have been awarded a Knowledge Transfer Partnership (KTP) grant from the Technology Strategy Board and Medical Research Council to optimise, validate and commercialise new preclinical assays for wound repair.
The partnership will see the transfer of novel preclinical models for cutaneous wound healing, developed at the University of Manchester within Dr Matthew Hardman’s laboratory, to Epistem’s Contract Research Services (CRS) division.
A KTP Associate has been appointed to work within Epistem on the project. Dr Hardman is a world-leading expert in molecular and cellular aspects of pathological healing and heads a multi-disciplinary research group within the Manchester Healing Foundation Centre for Tissue Regeneration at the University.
Epistem’s CRS division provides specialised preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammatory bowel disease, wound healing and skincare.
Epistem are experienced in commercialising new technologies and the partnership will allow the company to expand its existing range of wound healing models and to provide a broad, innovative service range.
Dr Hardman, who is based in the University’s Faculty of Life Sciences, said: “It is a real privilege to be awarded the first ever KTP grant to be sponsored by the Medical Research Council. This partnership represents a tremendous opportunity to realise the potential of our work.”
Catherine Booth, Managing Director at Epistem, added: “We are delighted to be working with Dr Hardman, who is a highly regarded wound healing expert, and to be able to provide our customers with access to cutting edge preclinical models”
For further information on Epistem please visit www.epistem.co.uk